• Mira Pharmaceuticals disclosed positive preclinical formulation results for MIRA-55, its oral non-opioid candidate for chronic inflammatory pain.
• Results have already been presented, with the lead formulation showing favorable oral absorption and consistent distribution to brain and liver tissue.
• Management framed the findings as strengthening the case for an oral therapy targeting both central pain processing and peripheral inflammation.
• The update extends earlier preclinical efficacy work that showed pain and inflammation improvements versus morphine in an inflammatory pain model.
• Further preclinical work is planned to link tissue exposure with pharmacodynamic activity and therapeutic effect ahead of later-stage development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032777), on July 10, 2026, and is solely responsible for the information contained therein.